Search results for: IgG2b
#34558462 // To Up
The Impact of IgG administration on the cellular immunity status in the patients with multidrug-resistant tuberculosis/HIV with CD4 + lymphocyte cells below 50 cells/ Î¼l.Treatment of the patients with multidrug-resistant tuberculosis (MDR-TB)/HIV coinfection in a state of severely suppressed immune system remains unsatisfactory.
Nina Matsegora, Antonina Kaprosh, Petro Antonenko
2911 related Products with: The Impact of IgG administration on the cellular immunity status in the patients with multidrug-resistant tuberculosis/HIV with CD4 + lymphocyte cells below 50 cells/ Î¼l.100 µg500IU100 µg1 mg
#34557376 2021/09/19 To Up
Results of Serosurveillance and Forecasting the Third Wave of COVID-19 in an Industrial District in India.Prevalence of immunoglobulin G (IgG) severe acute respiratory syndromeÂ coronavirus 2 (SARS-CoV-2) antibodies in the industrial district of East Singhbhum (Jharkhand, India) from July, August, November, and December 2020 and January 2021 after the first wave and in July 2021 after the second wave of coronavirus disease 2021 (COVID-19) infections may be utilized to find the possibility of a third wave of COVID-19 infections. Based on the trend of the loss of protective IgG antibodies after the first wave and the seropositivity of 75% in the district in July 2021, simple forecasting and proportional estimates of the seropositivity in the next eight months and the estimated maximum number of the cases was done. We also considered the seropositivity without vaccination in July 2021 (63%). Additionally, the trend of the weekly RT-PCR and rapid antigen testing for SARS-CoV-2 may also preemptively predict an imminent wave. Based on the East Singhbhum population and the vaccination coverage with at least one dose till July 2021 (Covishield or Covaxin), it is estimated that a 4-5%Â monthly vaccination coverage rate of new individuals will not allow the seropositivity to fall below 50% and hold at bay a major wave. Vaccination coverage of 3% or less would allow a continuous drop in acquired immunity in the district and can potentially cause a rise in cases, making the community susceptible to a future surge of infections. A 3-5% vaccination rate of new individuals is unlikely to see a drop in the community seropositivity below 50% and the number of new cases of COVID-19 infections going above 478 to 712 per month at least till March 2022. The assumptions are based on presuming that there will be no new mutant of SARS-CoV-2 that escapes the immunity provided by previous infection or vaccination over the next eight months. However, currently, there is no evidence to speculate on any new variant of concern causing a major wave globally. The B.1.617.2 (delta) variant was first identified in October 2020 and there was a lag of six months to the second surge of COVID-19 infections in East Singhbhum, primarily caused by this variant. Additionally, 3% and above, with a rising weekly trend of reverse transcription-polymerase chain reaction (RT-PCR) positivity for SARS-CoV-2 can provide at least four to eight weeks advance warning before the peak of the wave if an imminent future wave is impending.
Deb Sanjay Nag, Minakshi Mishra, Rajan Chaudhry, Farah Rana, Sudhir Rai, Neelam Mehta, Minakshi Gupta
2245 related Products with: Results of Serosurveillance and Forecasting the Third Wave of COVID-19 in an Industrial District in India.100 μg
#34556154 2021/09/23 To Up
Tubulointerstitial nephritis and uveitis syndrome following meningitis and systemic lymphadenopathy with persistent Toxoplasma immunoglobulin M: a case report.Tubulointerstitial nephritis and uveitis syndrome is a rare lymphocyte-related oculorenal inflammatory disease presumed to be associated with drug use and infectious agents. ToxoplasmaÂ gondii is one of such pathogens that could exhibit encephalitis, meningitis, and uveitis in immunocompromised or in some immunocompetent individuals. If the immunoglobulin M of Toxoplasma is positive on screening, the interpretation of the result is not simple, especially when immunoglobulin M stays positive persistently.
Yoshihiro Oya, Hidekazu Futami, Takuya Nakazawa, Kazuyuki Ishijima, Keiko Umemiya, Fumiyoshi Takizawa, Naoki Imai, Hiroshi Kitamura, Ryutaro Matsumura
2630 related Products with: Tubulointerstitial nephritis and uveitis syndrome following meningitis and systemic lymphadenopathy with persistent Toxoplasma immunoglobulin M: a case report.1000 tests100ug200 10 mg25 mg10 mg100ul500 mg1 ml 5 G 5 G100ug
#34556058 2021/09/23 To Up
The host immune response of a discharged COVID-19 patientÂ with twice reemergence of SARS-CoV-2: a case report.The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic. There have been reports that long-term SARS-CoV-2 RNA shedding and re-infection of COVID-19 patients existed. However, the specific mechanism, diagnosis, and treatment of COVID-19 are still unclarified.
Xiaobin Zao, Yang Zhou, Yijun Liang, Xu Cao, Hening Chen, Xiaoke Li, Yong'an Ye
2935 related Products with: The host immune response of a discharged COVID-19 patientÂ with twice reemergence of SARS-CoV-2: a case report.100 ul100 ug50 ug 1.0 mg100 ul100 ul100 ul
#34555004 2021/09/24 To Up
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.Three COVID-19 vaccines are authorized or approved for use among adults in the United States (1,2). Two 2-dose mRNA vaccines, mRNA-1273 from Moderna and BNT162b2 from Pfizer-BioNTech, received Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) in December 2020 for persons aged â¥18 years and aged â¥16 years, respectively. A 1-dose viral vector vaccine (Ad26.COV2 from Janssen [Johnson & Johnson]) received EUA in February 2021 for persons aged â¥18 years (3). The Pfizer-BioNTech vaccine received FDA approval for persons aged â¥16 years on August 23, 2021 (4). Current guidelines from FDA and CDC recommend vaccination of eligible persons with one of these three products, without preference for any specific vaccine (4,5). To assess vaccine effectiveness (VE) of these three products in preventing COVID-19 hospitalization, CDC and collaborators conducted a case-control analysis among 3,689 adults aged â¥18 years who were hospitalized at 21 U.S. hospitals across 18 states during March 11-August 15, 2021. An additional analysis compared serum antibody levels (anti-spike immunoglobulin G [IgG] and anti-receptor binding domain [RBD] IgG) to SARS-CoV-2, the virus that causes COVID-19, among 100 healthy volunteers enrolled at three hospitals 2-6 weeks after full vaccination with the Moderna, Pfizer-BioNTech, or Janssen COVID-19 vaccine. Patients with immunocompromising conditions were excluded. VE against COVID-19 hospitalizations was higher for the Moderna vaccine (93%; 95% confidence interval [CI]Â =Â 91%-95%) than for the Pfizer-BioNTech vaccine (88%; 95% CIÂ =Â 85%-91%) (p = 0.011); VE for both mRNA vaccines was higher than that for the Janssen vaccine (71%; 95% CIÂ =Â 56%-81%) (all p<0.001). Protection for the Pfizer-BioNTech vaccine declined 4 months after vaccination. Postvaccination anti-spike IgG and anti-RBD IgG levels were significantly lower in persons vaccinated with the Janssen vaccine than the Moderna or Pfizer-BioNTech vaccines. Although these real-world data suggest some variation in levels of protection by vaccine, all FDA-approved or authorized COVID-19 vaccines provide substantial protection against COVID-19 hospitalization.
Wesley H Self, Mark W Tenforde, Jillian P Rhoads, Manjusha Gaglani, Adit A Ginde, David J Douin, Samantha M Olson, H Keipp Talbot, Jonathan D Casey, Nicholas M Mohr, Anne Zepeski, Tresa McNeal, Shekhar Ghamande, Kevin W Gibbs, D Clark Files, David N Hager, Arber Shehu, Matthew E Prekker, Heidi L Erickson, Michelle N Gong, Amira Mohamed, Daniel J Henning, Jay S Steingrub, Ithan D Peltan, Samuel M Brown, Emily T Martin, Arnold S Monto, Akram Khan, Catherine L Hough, Laurence W Busse, Caitlin C Ten Lohuis, Abhijit Duggal, Jennifer G Wilson, Alexandra June Gordon, Nida Qadir, Steven Y Chang, Christopher Mallow, Carolina Rivas, Hilary M Babcock, Jennie H Kwon, Matthew C Exline, Natasha Halasa, James D Chappell, Adam S Lauring, Carlos G Grijalva, Todd W Rice, Ian D Jones, William B Stubblefield, Adrienne Baughman, Kelsey N Womack, Christopher J Lindsell, Kimberly W Hart, Yuwei Zhu, Lisa Mills, Sandra N Lester, Megan M Stumpf, Eric A Naioti, Miwako Kobayashi, Jennifer R Verani, Natalie J Thornburg, Manish M Patel,
2979 related Products with: Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.100 μg100 μg5 mg100 μg100 μg100 μg100 μg100 μg100 μg100 μg
Error loading info... Pleas try again later.
#34553591 2021/09/23 To Up
One-Step Electrochemical Growth of 2D/3D Zn(II)-MOF Hybrid Nanocomposites on an Electrode and Utilization of a [email protected] MOF Nanocatalyst for Electrochemical Immunoassay.To date, two-dimensional (2D) and three-dimensional (3D) metal organic frameworks (MOFs) have been promising materials for applications in electrocatalysis, separation, and sensing. However, the exploration of a simple method for simultaneous fabrication of 2D/3D MOFs on a surface remains challenging. Herein, a one-step and in situ electrosynthesis strategy for fabrication of 2D Hemin-bridged MOF sheets (Hemin-MOFs) or 2D/3D Zn(II)-MOF hybrid nanocomposites on an electrode is reported. It exhibits varied morphologies at different electrodeposition times and attains a 2D/3D complex morphology by adding 1,3,5-benzenetricarboxylic acid (HBTC) as an organic ligand. The morphology and size of 2D Hemin-MOFs are important factors that influence their performance. Since Pt nanoparticles (PtNPs) are grown on 2D Hemin-MOF sheets, this composite can serve as the peroxidase mimics and PtNPs can act as an anchor to capture the antibody. Therefore, this hybrid nanosheet-modified electrode is used as an electrochemical sensing platform for ultrasensitive pig immunoglobulin G (IgG) and the surface-protective antigen (Spa) protein of immunodetection. Moreover, this work provides a new avenue for the electrochemical synthesis of 2D/3D MOF hybrid nanocomposites with a high surface area and biomimetic catalysts.
Daili Tang, Xiaolan Yang, Birui Wang, Yanbin Ding, Siyu Xu, Junjie Liu, Yang Peng, Xinglong Yu, Zhaohong Su, Xiaoli Qin
2083 related Products with: One-Step Electrochemical Growth of 2D/3D Zn(II)-MOF Hybrid Nanocomposites on an Electrode and Utilization of a [email protected] MOF Nanocatalyst for Electrochemical Immunoassay.100 mg96 Tests/kit0.1 mg1000 tests100μg200 100ug16 Arrays/Slide25 mg10 mg200ug500 MG
#34551974 // To Up
Transdermal vaccination via 3D-printed microneedles induces potent humoral and cellular immunity.Vaccination is an essential public health measure for infectious disease prevention. The exposure of the immune system to vaccine formulations with the appropriate kinetics is critical for inducing protective immunity. In this work, faceted microneedle arrays were designed and fabricated utilizing a three-dimensional (3D)-printing technique called continuous liquid interface production (CLIP). The faceted microneedle design resulted in increased surface area as compared with the smooth square pyramidal design, ultimately leading to enhanced surface coating of model vaccine components (ovalbumin and CpG). Utilizing fluorescent tags and live-animal imaging, we evaluated in vivo cargo retention and bioavailability in mice as a function of route of delivery. Compared with subcutaneous bolus injection of the soluble components, microneedle transdermal delivery not only resulted in enhanced cargo retention in the skin but also improved immune cell activation in the draining lymph nodes. Furthermore, the microneedle vaccine induced a potent humoral immune response, with higher total IgG (Immunoglobulin G) and a more balanced IgG1/IgG2a repertoire and achieved dose sparing. Furthermore, it elicited T cell responses as characterized by functional cytotoxic CD8 T cells and CD4 T cells secreting Th1 (T helper type 1)-cytokines. Taken together, CLIP 3D-printed microneedles coated with vaccine components provide a useful platform for a noninvasive, self-applicable vaccination.
Cassie Caudill, Jillian L Perry, Kimon Iliadis, Addis T Tessema, Brian J Lee, Beverly S Mecham, Shaomin Tian, Joseph M DeSimone
1461 related Products with: Transdermal vaccination via 3D-printed microneedles induces potent humoral and cellular immunity.200ul50 ug 50μg/vial100ug/vial25 mg1000 TESTS/0.65ml100 per bag, 10 bags per100 ug/vial1000 tests100ug3x 500 ml1000pcs
#34551012 2021/09/22 To Up
Measles antibody seropositivity among children with allergic diseases: A cross-sectional study in the Japan Environment & Children's Pilot Study.The relationship between allergic individuals and their responsiveness to routine vaccines has rarely been investigated. This study examined whether the seroprevalence of measles antibody differed between children with and without allergic diseases in the general pediatric population.
Mayako Saito-Abe, Kiwako Yamamoto-Hanada, Kensuke Shoji, Miori Sato, Makoto Irahara, Yu Taniguchi, Makiko Sekiyama, Nathan Mise, Akihiko Ikegami, Masayuki Shimono, Reiko Suga, Masafumi Sanefuji, Shouichi Ohga, Masako Oda, Hiroshi Mitsubuchi, Isao Miyairi, Yukihiro Ohya
1596 related Products with: Measles antibody seropositivity among children with allergic diseases: A cross-sectional study in the Japan Environment & Children's Pilot Study.500 tests500 tests1 Set50ul4 Arrays/Slide1 Set
No related Items
#34549671 2021/09/22 To Up
Short-term consumption of alcohol (vodka) mixed with energy drink (AMED) attenuated alcohol-induced cerebral capillary disturbances and neuroinflammation in adult wild-type mice.The ingestion of combinatory Alcohol Mixed with Energy Drink (AMED) beverages continues to increase markedly, particularly among young adults. Some studies suggest detrimental health effects related to the combination of alcohol with energy drink formulations; however, the consumption of AMED has not been investigated in context of the cerebral microvasculature or neuroinflammation. We hypothesized that cerebral capillary integrity and glial cells are particularly vulnerable to the combination of AMED.12-week old wild-type C57BL/6J mice were orally gavaged with either vehicle (water), alcohol (vodka), an energy drink (Mother), or a combination AMED, daily for five days. Thereafter, mice were sacrificed, blood alcohol concentrations were analysed and cryosections of brain specimens were subjected to confocal immunofluorescent analysis for measures of cerebral capillary integrity via immunoglobulin G (IgG), and markers of neuroinflammation, ionized-calcium-binding-adaptor-molecule 1 (Iba1) and Glial-Fibrillary-Acidic-Protein (GFAP). Proinflammatory cytokines, IL-2, IL-17A, IFN-Ï, and anti-inflammatory cytokines, IL-4, IL-6 and IL-10, were also measured in serum. Consistent with previous studies, cerebral capillary dysfunction and astroglial cell activation were markedly greater in the alcohol-only group (AO); however, the AO-induced effects were profoundly attenuated with the AMED combination. Mice maintained on AO and AMED interventions exhibited a moderate increase in microglial recruitment. There were no significant changes in pro-inflammatory nor anti-inflammatory cytokines in ED or AMED treated mice. This study suggests that paradoxically the acute detrimental effects of alcohol on cerebral capillary integrity and astrogliosis are counteracted with the co-provision of an ED, rich in caffeine and taurine and containing B-group vitamins.
Ryusuke Takechi, John Mamo, Sukanya Das, Liam Graneri, Zachary D'Alonzo, Michael Nesbit, Edwin Junaldi, Virginie Lam
2877 related Products with: Short-term consumption of alcohol (vodka) mixed with energy drink (AMED) attenuated alcohol-induced cerebral capillary disturbances and neuroinflammation in adult wild-type mice.100 96T5 g1 ml 100ul100ug 5 G100 μg100ug100 μg50
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia